These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Bartolucci P; Ramanoelina J; Cohen P; Mahr A; Godmer P; Le Hello C; Guillevin L Rheumatology (Oxford); 2002 Oct; 41(10):1126-32. PubMed ID: 12364631 [TBL] [Abstract][Full Text] [Related]
6. Infliximab in patients with systemic vasculitis that is difficult to treat: poor outcome and significant adverse effects. Sangle SR; Hughes GR; D'Cruz DP Ann Rheum Dis; 2007 Apr; 66(4):564-5. PubMed ID: 17360788 [No Abstract] [Full Text] [Related]
7. Pulmonary sarcoidosis in a patient with psoriatic arthritis during infliximab therapy. Izzi S; Francesconi F; Visca P; Altieri A; De Mutiis C; Trevisan G; Bonifati C Dermatol Online J; 2010 May; 16(5):16. PubMed ID: 20492833 [TBL] [Abstract][Full Text] [Related]
8. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Booth AD; Jayne DR; Kharbanda RK; McEniery CM; Mackenzie IS; Brown J; Wilkinson IB Circulation; 2004 Apr; 109(14):1718-23. PubMed ID: 15037536 [TBL] [Abstract][Full Text] [Related]
9. Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis. Mukhtyar C; Luqmani R Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv31-6. PubMed ID: 16239383 [TBL] [Abstract][Full Text] [Related]
11. Feasibility of 1 hour infliximab infusions. van Vollenhoven RF; Gullström E; Klareskog L Ann Rheum Dis; 2005 Apr; 64(4):654. PubMed ID: 15769930 [No Abstract] [Full Text] [Related]
12. Is it safe to readminister tumor necrosis factor alpha antagonists following tuberculosis flare? Aslanidis S; Pyrpasopoulou A; Douma S; Petidis K Arthritis Rheum; 2008 Jan; 58(1):327-8. PubMed ID: 18163500 [No Abstract] [Full Text] [Related]
13. [Should we be afraid of the anti-TNFalpha drugs in 2008?]. Gaudin P Rev Med Interne; 2008 Dec; 29(12):971-4. PubMed ID: 18571291 [No Abstract] [Full Text] [Related]
14. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. Booth A; Harper L; Hammad T; Bacon P; Griffith M; Levy J; Savage C; Pusey C; Jayne D J Am Soc Nephrol; 2004 Mar; 15(3):717-21. PubMed ID: 14978174 [TBL] [Abstract][Full Text] [Related]
15. Wegener's granulomatosis with a possible thyroidal involvement. Ozdogu H; Boga C; Bolat F; Ertorer ME J Natl Med Assoc; 2006 Jun; 98(6):956-8. PubMed ID: 16775921 [TBL] [Abstract][Full Text] [Related]
16. [Biologicals in the treatment of rheumatic diseases]. Scherer HU; Burmester GR Dtsch Med Wochenschr; 2006 Oct; 131(41):2279-85. PubMed ID: 17036270 [No Abstract] [Full Text] [Related]
18. Therapy for severe necrotizing vasculitis with infliximab. Mang R; Ruzicka T; Stege H J Am Acad Dermatol; 2004 Aug; 51(2):321-2. PubMed ID: 15280860 [No Abstract] [Full Text] [Related]
19. Successful treatment of meningeal involvement in Wegener's granulomatosis with infliximab. Hermann J; Reittner P; Scarpatetti M; Graninger W Ann Rheum Dis; 2006 May; 65(5):691-2. PubMed ID: 16611871 [No Abstract] [Full Text] [Related]
20. Cutaneous vasculitis induced by TNF inhibitors: a report of three cases. Fujikawa K; Kawakami A; Hayashi T; Iwamoto N; Kawashiri SY; Aramaki T; Ichinose K; Tamai M; Arima K; Kamachi M; Yamasaki S; Nakamura H; Ida H; Origuchi T; Eguchi K Mod Rheumatol; 2010 Feb; 20(1):86-9. PubMed ID: 19812889 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]